{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:02:16Z","timestamp":1780038136880,"version":"3.53.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rare M6-subtype antimitochondrial antibody (AMA-M6) has been described in patients treated with iproniazid, an antidepressant drug. Diagnosis can be made by identifying its highly characteristic indirect immunofluorescence pattern on rat organ substrates. In the existing literature, the presence of AMA-M6 has been associated with hepatitis cytolysis, with a favorable outcome following the discontinuation of treatment. This report presents two cases of AMA-M6-like pattern in patients who had never taken iproniazid. In the first case, the patient was receiving pembrolizumab treatment for lung adenocarcinoma. The presence of this pattern was identified 20 days after introducing immunotherapy, with a diagnosis of liver cytolysis made 10 days later, associated with the presence of nodular regenerative hyperplasia. Following the suspension of the injection, liver enzyme levels decreased and the pembrolizumab treatment was resumed with no recurrence of liver damage. In the second case, the same AMA-M6-like pattern was discovered fortuitously in a patient presenting with a complaint of dry mouth only, and no evidence of liver damage. In contrast to previous reports, our findings do not support the presence of MAO-B\u2013specific autoantibodies in these patients, and the target antigen remains to be identified. These two cases demonstrate that AMA-M6-like pattern can develop in patients who have never been exposed to iproniazid. While liver damage was present in one case, the patient remained asymptomatic in the second case. Immunologists must thus watch for uncommon patterns in indirect immunofluorescence to ensure appropriate medical care and patient follow-up.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1675688","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:09:06Z","timestamp":1780034946000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Two atypical cases of M6-like antimitochondrial antibody pattern unlinked to iproniazid"],"prefix":"10.3389","volume":"17","author":[{"given":"Elise","family":"Tolmer","sequence":"first","affiliation":[{"name":"Immunology Department, Clermont-Ferrand University Hospital","place":["Clermont-Ferrand, France"]},{"name":"Immunology Laboratory, UNH UMR1019, University of Clermont Auvergne, INRAE","place":["Clermont-Ferrand, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bonnet","sequence":"additional","affiliation":[{"name":"Immunology Department, Clermont-Ferrand University Hospital","place":["Clermont-Ferrand, France"]},{"name":"Immunology Laboratory, UNH UMR1019, University of Clermont Auvergne, INRAE","place":["Clermont-Ferrand, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Jeannin","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Department, Clermont-Ferrand University Hospital","place":["Clermont-Ferrand, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Junda","sequence":"additional","affiliation":[{"name":"Immunology Department, Clermont-Ferrand University Hospital","place":["Clermont-Ferrand, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Godignon","sequence":"additional","affiliation":[{"name":"Immunology Department, Clermont-Ferrand University Hospital","place":["Clermont-Ferrand, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Evrard","sequence":"additional","affiliation":[{"name":"Immunology Department, Clermont-Ferrand University Hospital","place":["Clermont-Ferrand, France"]},{"name":"Immunology Laboratory, UNH UMR1019, University of Clermont Auvergne, INRAE","place":["Clermont-Ferrand, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000171347","article-title":"Antimitochondrial antibodies in primary biliary cirrhosis and other disorders: definition and clinical relevance","volume":"10","author":"Berg","year":"1992","journal-title":"Dig Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/BF01728613","article-title":"Mitochondrial antigens and autoantibodies: from anti-M1 to anti-M9","volume":"64","author":"Berg","year":"1986","journal-title":"Klin Wochenschr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0528.2002.017402.x","article-title":"Primary biliary cirrhosis: an orchestrated immune response against epithelial cells","volume":"174","author":"Gershwin","year":"2000","journal-title":"Immunol Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1040503","article-title":"Identification and characterization of four M2 mitochondrial autoantigens in primary biliary cirrhosis","volume":"9","author":"Bassendine","year":"2008","journal-title":"Semin Liver Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet"},{"key":"B6","first-page":"93","article-title":"A new antimitochondria antibody (anti-M6) in iproniazid-induced hepatitis","volume":"47","author":"Homberg","year":"1982","journal-title":"Clin Exp Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.0021","article-title":"Human anti-mitochondria autoantibodies appearing in iproniazid-induced immunoallergic hepatitis recognize human liver monoamine oxidase B","volume":"218","author":"Pons","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000096997","article-title":"Evolution of the diffuse neuroendocrine system--clear cells and cloudy origins","volume":"84","author":"Modlin","year":"2006","journal-title":"Neuroendocrinology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-016-0959-z","article-title":"PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues","volume":"21","author":"Hamanishi","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13541","article-title":"Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients","volume":"11","author":"Song","year":"2020","journal-title":"Thorac Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1415470","article-title":"Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis","volume":"14","author":"Pasello","year":"2024","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0070-RA","article-title":"Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy","volume":"145","author":"Patil","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30157","article-title":"Nodular regenerative hyperplasia associated with immune checkpoint blockade","volume":"68","author":"LoPiccolo","year":"2018","journal-title":"Hepatology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1186\/s12885-025-14171-3","article-title":"The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"key":"B19","article-title":"Statins","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":""},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1095694","article-title":"Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2517522","article-title":"Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod: case report","volume":"17","author":"Cobelas-Cartagena","year":"2025","journal-title":"Immunotherapy"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor\u2013induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1675688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:09:07Z","timestamp":1780034947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1675688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2026.1675688"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1675688","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1675688"}}